Short-term efficacy of intravitreal aflibercept depending on angiographic classification of polypoidal choroidal vasculopathy

Abstract

NCT02597855, Results.

Presenting characteristics and prevalence of polypoidal choroidal vasculopathy in Scandinavian patients with treatment‐naïve exudative age‐related macular degeneration

“…In Taiwan, Yeung et al (2017) found that PCV type 1 presented with worse BCVA than PCV type 2. Polypoidal choroidal vasculopathy (PCV) type 1 responds better to anti-VEGF treatment than PCV type 2 (Jeong & Sagong 2017;Nakai et al 2017), whereas photodynamic therapy yield better outcomes for PCV type 2 (Honda et al 2014). In our study, we find that these associations are not exclusive for Asian populations and are also present in Caucasians.…”

“…In our study, we find that these associations are not exclusive for Asian populations and are also present in Caucasians. Interestingly, PCV type 2 also presents with a thicker choroid than PCV type 1 (Jeong & Sagong 2017). Polypoidal choroidal vasculopathy (PCV) type 1 responds better to anti-VEGF treatment than PCV type 2 (Jeong & Sagong 2017;Nakai et al 2017), whereas photodynamic therapy yield better outcomes for PCV type 2 (Honda et al 2014).…”

Aflibercept Treatment in Polypoidal Choroidal Vasculopathy: Results of a Prospective Study in a Caucasian Population

“…Jeong and Sagong [20] found that type 1 PCV showed better visual improvement with a higher percentage of polyp regression than type 2 PCV with aflibercept treatment. In this study, we did not find any statistical difference between types 1 and 2 in either functional or anatomical results.…”

Comparison of the 12-Month Outcomes of Intravitreal Ranibizumab between Two Angiographic Subtypes of Polypoidal Choroidal Vasculopathy

“…This result might be associated with some type 2 PCV cases showing remarkable visual loss with recurrences during the follow-up period. A recent report described better visual and anatomical outcomes of intravitreal aflibercept in type 1 PCV than type 2 PCV over 6 months of follow-up [20] . Those results were in contrast to our previous report, which demonstrated that type 2 PCV showed a better visual outcome of PDT than type 1 PCV [15] .…”

“…We considered the reasons why previous studies often documented that typical neovascular AMD showed better outcomes of anti-VEGF therapies than PCV and hypothesized that the inclusion of type 2 PCV cases in those studies might influence their results. Type 2 PCV is reported to have larger polyp size than type 1 PCV, which often causes insufficient regression of polypoidal lesions with anti-VEGF therapy and may be a source of recurrence over time [20] . However, the proportion of cases that showed recurrence by 12 months after the initial IVR was relatively smaller in type 2 PCV than type 1 PCV, although it was not statistically significant, which suggests the existence of variations in type 2 PCV associated with the response to IVR.…”